  | Delgadillo, J., Kerkelä, E., Waters, A., van den Akker, E., LECHANTEUR, C., BAUDOUX, E., Gardiner, N., De Vos, J., & Vives, J. (2023). A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe. Cytotherapy. doi:10.1016/j.jcyt.2023.08.001  Peer Reviewed verified by ORBi |
 | Servais, S., Baron, F., LECHANTEUR, C., Seidel, L., BAUDOUX, E., BRIQUET, A., Selleslag, D., Maertens, J., Poire, X., Schroyens, W., Graux, C., De Becker, A., Zachee, P., Ory, A., Herman, J., Kerre, T., & Beguin, Y. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1106464 Peer Reviewed verified by ORBi |
 | Reenaers, C., GILLARD, R., Coimbra, C., GILLARD, R., Meunier, P., LECHANTEUR, C., BAUDOUX, E., BOUTAFFALA, L., Beguin, Y., & Louis, E. (2023). Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s disease: results from a prospective monocentric study. Journal of Crohn's and Colitis, 17, 728-737. doi:10.1093/ecco-jcc/jjac192 Peer Reviewed verified by ORBi |
 | GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211. Editorial Reviewed verified by ORBi |
 | VANDERMEULEN, M., Mohamed-Wais, M., ERPICUM, P., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., MAGGIPINTO, G., Jouret, F., Beguin, Y., & Detry, O. (2022). Infusion of allogeneic mesenchymal stromal cells after liver transplantation: Five-year follow-up. Liver Transplantation, 28, 636-646. doi:10.1002/lt.26323 Peer reviewed |
 | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154 Peer Reviewed verified by ORBi |
  | MALAISE, O., PAULISSEN, G., DEROYER, C., Cirgea, F., Poulet, C., LECHANTEUR, C., Brondello, J.-M., DE SENY, D., & MALAISE, M. (December 2021). Influence des glucocorticoïdes sur les caractéristiques de la sénescence cellulaire dans les fibroblastes synoviaux d’origine arthrosique. Revue du Rhumatisme, 88 (S1), 157. Peer reviewed |
 | MALAISE, O.* , PAULISSEN, G.* , DEROYER, C., Ciregia, F., Poulet, C., NEUVILLE, S., PLENER, Z., DANIEL, C., Gillet, P., LECHANTEUR, C., Brondello, J.-M., DE SENY, D.* , & MALAISE, M.*. (16 November 2021). Influence of Glucocorticoids on Cellular Senescence Hallmarks in Osteoarthritic Fibroblast-like Synoviocytes. Journal of Clinical Medicine, 10 (22), 5331. doi:10.3390/jcm10225331 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (October 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. United European Gastroenterology. Peer reviewed |
 | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., Pariente, B., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & LOUIS, E. (July 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. 16th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2021 Virtual. Peer reviewed |
 | LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., & BEGUIN, Y. (2021). MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells, 10, 1320. doi:10.3390/cells10061320 Peer Reviewed verified by ORBi |
 | VANDERMEULEN, M., ERPICUM, P., WEEKERS, L., BRIQUET, A., LECHANTEUR, C., Detry, O., Beguin, Y., & Jouret, F. (May 2020). Mesenchymal Stromal Cells in Solid Organ Transplantation. Transplantation, 104 (5), 923-936. doi:10.1097/TP.0000000000003077 Peer Reviewed verified by ORBi |
 | HAUZEUR, J.-P., LECHANTEUR, C., BAUDOUX, E., De Maertelaer, V., Pather, S., Katz, R., Malaise, M., Ino, J., & Beguin, Y. (2020). Did Osteoblastic Cell Therapy Improve the Prognosis of Prefracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clinical Orthopaedics and Related Research, 478, 1307-1315. Peer Reviewed verified by ORBi |
 | Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619 Peer Reviewed verified by ORBi |
 | ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020 Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001 Peer Reviewed verified by ORBi |
 | WEEKERS, L., ERPICUM, P., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (16 March 2017). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. 24th Annual Meeting, Bruxelles, Belgium. |
 | GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc. Peer reviewed |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12. Peer Reviewed verified by ORBi |
 | GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc. Peer reviewed |
 | HAUZEUR, J.-P., Tungouz, M., LECHANTEUR, C., Beguin, Y., BAUDOUX, E., de maertelaer, V., Pather, S., Katz, R., Ino, J., Egrise, D., Malaise, M., & Gangji, V. (October 2016). Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale : étude randomisée. Revue de Chirurgie Orthopédique et Traumatologie, 102, 73. doi:10.1016/j.rcot.2016.08.002 Peer reviewed |
 | Erpicum, P., WEEKERS, L., DETRY, O., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (28 April 2016). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. Annual Meeting of the BVN-SBN, Bruxelles, Belgium. |
 | Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society. |
 | SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235. Peer Reviewed verified by ORBi |
 | LECHANTEUR, C., BRIQUET, A., GIET, O., DELLOYE, O., BAUDOUX, E., & BEGUIN, Y. (2016). Clinical - scale expansion of mesenchymal stromal cells: a large banking experience. Journal of Translational Medicine, 14, 145-159. doi:10.1186/s12967-016-0892-y Peer Reviewed verified by ORBi |
 | WEEKERS, L., Erpicum, P., DETRY, O., BONVOISIN, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (2016). administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Transplant International, 29 (Suppl 2), 13 -p6. Peer Reviewed verified by ORBi |
 | WEEKERS, L., ERPICUM, P., DETRY, O., JOURET, F., LECHANTEUR, C., DELBOUILLE, M.-H., BRIQUET, A., BAUDOUX, E., & BEGUIN, Y. (November 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. Transplant International, 28 (S4), 223-224/BO278. Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., HONORE, P., & BEGUIN, Y. (November 2015). Infusion of third-party mesenchymal stem cells after liver transplantation: a phase-1, open-label, clinical study. Transplant International, 28 (S4), 10/O27. Peer Reviewed verified by ORBi |
 | WEEKERS, L., ERPICUM, P., DETRY, O., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (May 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. American Journal of Transplantation, 15 (suppl 3). Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (April 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Journal of Hepatology, 62 (S2), 311 (P0052. Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (27 March 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study [Poster presentation]. 22nd Annual Meeting, Brussels, Belgium. |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (March 2015). Infusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study. Acta Gastro-Enterologica Belgica, 78 (1), 29. Peer Reviewed verified by ORBi |
 | Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597 Peer Reviewed verified by ORBi |
 | DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56. Peer reviewed |
 | Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279 Peer Reviewed verified by ORBi |
 | Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9 Peer Reviewed verified by ORBi |
 | BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003 Peer Reviewed verified by ORBi |
 | Erpicum, P., DETRY, O., WEEKERS, L., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2014). Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation, 29, 1487-1493. doi:10.1093/ndt/gft538 Peer Reviewed verified by ORBi |
 | MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068 Peer Reviewed verified by ORBi |
 | LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222 Peer Reviewed verified by ORBi |
 | VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418 Peer Reviewed verified by ORBi |
 | DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., SQUIFFLET, J.-P., Honoré, P., DELVENNE, P., MEURISSE, M., BAUDOUX, E., & BEGUIN, Y. (30 May 2013). INFUSION OF THIRD-PARTY MESENCHYMAL STEM CELLS (MSC) AFTER KIDNEY AND LIVER TRANSPLANTATION: A PHASE I-II, OPEN-LABEL, CLINICAL STUDY (EudraCT 2011-001822-81 & NCT01429038) [Poster presentation]. 13eme rencontre de Beaune, Beaune, France. |
 | Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15. |
 | BRIQUET, A., HALLEUX, A., LECHANTEUR, C., & BEGUIN, Y. (2013). Neuropeptides to replace serum in cryopreservation of mesenchymal stromal cells ? Cytotherapy, 15, 1385-1394. doi:10.1016/j.jcyt.2013.06.012 Peer Reviewed verified by ORBi |
 | Hauzeur, J.-P., Bernard, C., Egrise, D., Kurth, W., Van Cauwenberge, H., LECHANTEUR, C., Gillet, P., Beguin, Y., MALAISE, M., & HUSTINX, R. (2013). (111)Indium-oxine labelling for evaluating the homing process of autologous osteoblasts implanted percutaneously in atrophic nonunion fractures. International Orthopaedics, 37 (1), 131-6. doi:10.1007/s00264-012-1719-y Peer Reviewed verified by ORBi |
 | DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., DELVENNE, P., BAUDOUX, E., & BEGUIN, Y. (19 October 2012). Infusion of third party mesenchymal stem cells (MSC) after kidney and liver transplantation: a phase I-II, open-label, clinical study [Paper presentation]. 4th Expert meeting, Barcelona, Spain. |
 | Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease [Poster presentation]. Belgian Hematological Society General Annual Meeting. |
 | BERNARD, C., HAUZEUR, J.-P., LECHANTEUR, C., VAN CAUWENBERGE, H., BEGUIN, Y., MALAISE, M., KURTH, W., GILLET, P., & HUSTINX, R. (2011). Evaluation of the homing process in the treatment of atrophic nonunion fractures by percutaneous autologous osteoblast cell implantation. Journal of Nuclear Medicine, 52 (SUPPL), 510. Peer Reviewed verified by ORBi |
 | Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011 Peer Reviewed verified by ORBi |
 | Zeddou, M., Briquet, A., Relic, B., Josse, C., Malaise, M., Gothot, A., Lechanteur, C., & Beguin, Y. (2010). The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biology International, 34 (7), 693-701. doi:10.1042/CBI20090414 Peer Reviewed verified by ORBi |
 | Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting. |
 | Robe, P., Nguyen-Khac, M.-T., Lambert, F., Lechanteur, C., Jolois, O., Ernst-Gengoux, P., Rogister, B., & Bours, V. (January 2007). Sufasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. International Journal of Oncology, 30 (1), 283-290. doi:10.3892/ijo.30.1.283 Peer Reviewed verified by ORBi |
 | Lechanteur, C., Jacobs, N., Greimers, R., Benoit, V., Deregowski, V., Chariot, A., Merville, M.-P., & Bours, V. (03 March 2005). Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis. Oncogene, 24 (10), 1788-1793. doi:10.1038/sj.onc.1208436 Peer Reviewed verified by ORBi |
 | Lechanteur, C., Delvenne, P., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J., Merville, M.-P., & Bours, V. (September 2000). Combined Suicide and Cytokine Gene Therapy for Peritoneal Carcinomatosis. Gut, 47 (3), 343-8. doi:10.1136/gut.47.3.343 Peer Reviewed verified by ORBi |
Lechanteur, C., Moutschen, M., Princen, F., Lopez, M.-J., Franzen, E., Gielen, J., Bours, V., & Merville, M.-P. (May 2000). Antitumoral Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-12-Expressing Dhd/K12 Colon Adenocarcinoma Cells. Cancer Gene Therapy, 7 (5), 676-82. doi:10.1038/sj.cgt.7700152 Peer Reviewed verified by ORBi |
Princen, F., Lechanteur, C., Lopez, M.-J., Gielen, J., Bours, V., & Merville, M.-P. (2000). Similar Efficiency of DNA-Liposome Complexes and Retrovirus-Producing Cells for Hsv-Tk Suicide Gene Therapy of Peritoneal Carcinomatosis. Journal of Drug Targeting, 8 (2), 79-89. doi:10.3109/10611860008996854 Peer Reviewed verified by ORBi |
 | Bentires-Alj, M., Hellin, A.-C., Lechanteur, C., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J.-L., Merville, M.-P., & Bours, V. (January 2000). Cytosine Deaminase Suicide Gene Therapy for Peritoneal Carcinomatosis. Cancer Gene Therapy, 7 (1), 20-6. doi:10.1038/sj.cgt.7700093 Peer Reviewed verified by ORBi |
Princen, F., Robe, P., Lechanteur, C., Mesnil, M., Rigo, J.-M., Gielen, J., Merville, M.-P., & Bours, V. (November 1999). A Cell Type-Specific and Gap Junction-Independent Mechanism for the Herpes Simplex Virus-1 Thymidine Kinase Gene/Ganciclovir-Mediated Bystander Effect. Clinical Cancer Research, 5 (11), 3639-44. Peer Reviewed verified by ORBi |
 | Princen, F., Lechanteur, C., Lopez Y Cadenas, M., Rocoux, G., Detroz, B., Gielen, J.-L., Fillet, G., Merville, M.-P., & Bours, V. (August 1998). Repeated Cycles of Retrovirus-Mediated Hsvtk Gene Transfer Plus Ganciclovir Increase Survival of Rats with Peritoneal Carcinomatosis. Gene Therapy, 5 (8), 1054-60. doi:10.1038/sj.gt.3300710 Peer Reviewed verified by ORBi |
 | Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J., Bours, V., & Merville, M.-P. (1998). Hsv-1 Thymidine Kinase Gene Therapy for Peritoneal Carcinomatosis. Advances in Experimental Medicine and Biology, 451, 115-9. doi:10.1007/978-1-4615-5357-1_18 Peer Reviewed verified by ORBi |
Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J.-L., Bours, V., & Merville, M.-P. (November 1997). Hsv-1 Thymidine Kinase Gene Therapy for Colorectal Adenocarcinoma-Derived Peritoneal Carcinomatosis. Gene Therapy, 4 (11), 1189-94. doi:10.1038/sj.gt.3300520 Peer Reviewed verified by ORBi |
 | Charlier, C., Bruyneel, E., Lechanteur, C., Bracke, M., Mareel, M., & Castronovo, V. (19 December 1996). Enhancement of Tamoxifen-Induced E-Cadherin Function by Ca2+ Channel Antagonists in Human Breast Cancer Mcf7/6 Cells. European Journal of Pharmacology, 317 (2-3), 413-6. doi:10.1016/S0014-2999(96)00816-3 Peer Reviewed verified by ORBi |